

## 5. <u>INTENDED PURPOSE</u>

HIVFIND Whole Blood HIV 1/2 antibody detection self test is a qualitative, screening, In-vitro diagnostic immunochromatography assay for the detection of antibodies specific to HIV (HIV1 & HIV-2) in whole blood. The test is intended to use by individuals in a private setting as a self test to aid in the diagnosis of HIV infection with self collected finger prick blood sample.

- 6. Basic UDI-DI: 890549HIVWBSFEL
- 7. **<u>PRODUCT CODES</u>** : HIVWBS-01, HIVWBS-02, HIVWBS-03, HIVWBS-04



Meril



### 8. <u>RISK CLASS</u>

# : Class D, Rule 1, Second Indent

HIVFIND Whole Blood HIV 1/2 antibody detection self test is classified as Class D, Rule 1 second indent as per Annex VIII of Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on In Vitro Diagnostic Medical Devices and Repealing Directive 98/79/EC and Commission Decision 2010/227/EU.

Devices intended to be used for the following purposes are classified as class D and comes under Rule 1 second indent: — Devices intended to be used for the detection of the presence of, or exposure to, a transmissible agent that causes a life-threatening disease with a high or suspected high risk of propagation.

HIVFIND Whole Blood HIV 1/2 antibody detection self test is intended for antibodies specific to HIV (HIV1 & HIV-2) in fingerprick whole blood. Thus, device is intended for detection of antibodies specific to HIV (HIV1 & HIV-2) in human blood. HIV1 & HIV2 virus is transmissible agent that causes HIV infection in human which is considered as life-threatening disease. Transmission of HIV infection is mainly by exposure to certain infected body fluids e.g., blood and blood components, genital secretions etc. and by transplacental route that can be a high risk of propagation of HIV infection in population where monitoring is critical in the process of patient management.

9. <u>NOTIFIED BODY</u>

Name	
Address	
<b>Notified Body Identification</b>	1
Number	
Description of the	
Conformity Assessment	
procedure	
The CE Certificate	
number	

Applicable	:
Guidelines/Standards/Commo	
Specifications (CS)	

- 3EC International a.s.
- Hranicna 18, 821 05 Bratislava, Slovak Republic
- 2265

:

:

:

:

- Annex IX Conformity assessment based on a quality management system and assessment of the technical documentation
- EU Technical Documentation Assessment Certificate No.: 2024-IVDR/TD-003 EU Quality Management System Certificate No.: 2024-IVDR/QS-003

EU IVDR 2017/746, EU 2022/1107, EN 13975:2003, EN 13641:2002, EN 13612:2002, EN 14136:2004, BS EN 62366-1:2015, EN ISO 13485:2016, EN ISO 13485:2016+A11:2021, ISO 14971:2019,BS EN ISO 14971:2019+A11:2021, EN ISO 18113-1:2011, EN ISO 18113-2:2011, BS EN ISO 18113-4:2011, EN ISO 15193:2009, EN ISO 15194:2009, EN ISO 17511:2021, EN ISO 23640:2015, EN ISO 15223-1:2021, ISO 14644-1: 2015, ISO 14644-2: 2015, BS EN ISO 14644-3: 2019, ISO EN ISO 20916:2019, MDCG 2022-2, 14644-4: 2001, MDCG 2020-7, MDCG 2020-8, MDCG 2022-9, MDCG

Meril

#### 2018-1, MDCG 2021-19, MDCG 2020-16

#### 10. STATEMENTS

We declare that our products as listed above in section 4.0, comply with the requirements to REGULATION (EU) 2017/746 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017, Annex IV and EU declaration of conformity is issued under the sole responsibility of Meril Diagnostics Pvt. Ltd.

- 1. The device that is covered by this declaration is in conformity with Regulation (EU) 2017/746 and if applicable, with any other relevant Union legislation that provides for the issuing of an EU declaration of conformity.
- 2. Company undertakes to manufacture the products as per National/International Standards and following quality management system as per EN ISO 13485:2016/ ISO 13485:2016/DIN EN ISO 13485:2016.
- 3. Company authorizes the notified body to carry out necessary audits and agrees to supply the required information & data/documents.
- 4. Company agrees to make available all relevant Documents & Data of the products to the National and Competent Authority for a period ending 10 (ten) years for IVDs after the last device covered by the EU declaration of conformity has been placed on the market.
- 5. Company &/or its authorized representative shall fulfill the obligations imposed by Annex IX of REGULATION (EU) 2017/746 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017 & shall ensure & declare that the Company's Products shall meet all provisions of the regulation as applicable.
- 6. Company undertakes to keep up to date a systematic procedure to review experience gained during post production phase and to implement appropriate means to apply any necessary corrective action taking account of the nature & risk in relation to the product.
- 7. Company undertakes to notify immediately any malfunction /deterioration of the performance of the device to the appropriate authority and shall recall such devices already placed in the market.
- 8. Company shall fulfill the obligations imposed by Annex I of REGULATION (EU) 2017/746 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 5 April 2017 and shall ensure and declare that the Company's Products shall meet all the provisions of the regulation as applicable.

:

:

:

:

:

#### 11. <u>APPROVAL</u>

Signature

For Meril Diagnostics Pvt. Ltd. Location Name Designation

Vapi, Gujarat, INDIA

- Mr. Narendra Patel
- General Manager, RA & QA

CS P CHALA DIA VAP dall

Date



# 12. AMENDMENT HISTORY:

Revision No.	Date	Amendment Description
00	12/09/2023	Initial Issue
01	As on Issue Date	The EU Technical Documentation Assessment Certificate No. and EU Quality Management System Certificate No. are updated.